v3.26.1
Note 10 - Segments (Tables)
3 Months Ended
Mar. 31, 2026
Notes Tables  
Segment Reporting [Table Text Block]

Three Months Ended March 31, 2026

 
  

Regenerative Biotech

  

Consumer Health Products

  

Consolidated Total

 

Revenue

 

Product revenue

 $—  $226  $226 

Significant Expense Categories (provided to CODM)

 

Cost of sales

  —   206   206 

Research and development

  563   —   563 

Sales and marketing

  2   16   18 

General and administrative (a)

  1,044   1   1,045 

Total significant segment expenses

  1,609   223   1,832 

Other Segment Items

 

Other segment items (b)

  5   —   5 

Segment net loss

 $(1,604) $3  $(1,601)

Three Months Ended March 31, 2025

 
  

Regenerative Biotech

  

Consumer Health Products

  

Consolidated Total

 

Revenue

 

Product revenue

 $—  $45  $45 

Significant Expense Categories (provided to CODM)

 

Cost of sales

  —   33   33 

Research and development

  601   —   601 

Sales and marketing

  8   2   10 

General and administrative (a)

  1,071   —   1,071 

Total significant segment expenses

  1,680   35   1,715 

Other Segment Items

 

Other segment items (b)

  11   —   11 

Segment net loss

 $(1,669) $10  $(1,659)
Segment Reporting, Reconciliation of Asset by Segment to Consolidated [Table Text Block]
  March 31,  December 31, 
  

2026

  

2025

 

Cash and cash equivalents:

        

Regenerative Biotech

 $127  $1,206 

Consumer Health Products

  292   146 

Total

 $419  $1,352 
         

Total assets:

        

Regenerative Biotech

 $1,225  $2,277 

Consumer Health Products

  573   400 

Total

 $1,798  $2,677